Literature DB >> 11171717

The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis.

E Daviskas1, S D Anderson, S Eberl, H K Chan, I H Young.   

Abstract

STUDY
OBJECTIVE: To investigate the acute effect of mannitol on the clearance of mucus, and (1) the 24-h mucus retention, and (2) the mucus clearance rate and lung function 24 h after inhalation of a single dose of mannitol.
DESIGN: Clearance of mucus was measured on 3 consecutive days using (99m)Tc-sulfur colloid radioaerosol and a gamma camera.
INTERVENTIONS: Mannitol, 330 +/- 68 mg (mean+/- SD), was inhaled using a dry powder inhaler only on day 2. PATIENTS: Eight patients with bronchiectasis (age range, 29 to 70 years). MEASUREMENTS AND
RESULTS: On each day, lung images were collected over 2 h and at 24 h. Key findings of the study are as follows: (1) the 24-h retention of mucus was reduced the day after mannitol had been inhaled, compared to the day without mannitol (day 1) in the whole right lung (57.6 +/- 6.2% vs 68.1 +/- 5.9%), central (47.5 +/- 6.7% vs 56.9 +/- 6.5%), intermediate (61.7 +/- 5.6% vs 73.8 +/- 5.5%), and peripheral regions (70.9 +/- 4.3% vs 86.6 +/- 4.6%)(p < 0.02); and (2) mannitol helped patients clear mucus within 2 h that might otherwise take up to 24 h, from the whole right lung and defined regions. However, clearance over 60 min measured 24 h after mannitol inhalation was not significantly different to baseline clearance without mannitol (8.7 +/- 1.9% on day 1 vs 9.7 +/- 3.7% 24 h after mannitol; p > 0.8). The patients maintained the same lung function the day before and after mannitol had been inhaled: FEV(1) (percent predicted), 79 +/- 5 on day 1 vs 80 +/- 5 on day 3; and forced expiratory flow, midexpiratory phase (percent predicted), 50 +/- 6 on day 1 vs 51 +/- 6 on day 3; p > 0.6).
CONCLUSIONS: Mannitol inhalation acutely increases clearance of mucus, and this effect extends beyond the acute study period, resulting in decreased mucus retention at 24 h.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11171717     DOI: 10.1378/chest.119.2.414

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

Review 1.  Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents.

Authors:  Jonathan Ilowite; Peter Spiegler; Heather Kessler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.

Authors:  Xiaojian Li; Frederick G Vogt; Don Hayes; Heidi M Mansour
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-02-06       Impact factor: 2.849

Review 3.  Resolution of cell-mediated airways diseases.

Authors:  Carl G Persson; Lena Uller
Journal:  Respir Res       Date:  2010-06-11

Review 4.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

Review 5.  New pulmonary therapies directed at targets other than CFTR.

Authors:  Scott H Donaldson; Luis Galietta
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

6.  Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis.

Authors:  A P Watt; V Brown; J Courtney; M Kelly; L Garske; J S Elborn; M Ennis
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

Review 7.  Inhaled mannitol for cystic fibrosis.

Authors:  Sarah J Nevitt; Judith Thornton; Clare S Murray; Tiffany Dwyer
Journal:  Cochrane Database Syst Rev       Date:  2018-02-09

8.  Inhaled mannitol for cystic fibrosis.

Authors:  Sarah J Nevitt; Judith Thornton; Clare S Murray; Tiffany Dwyer
Journal:  Cochrane Database Syst Rev       Date:  2020-05-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.